Details
Precautions:
Consult your veterinarian before using Phenylbutazone with phenytoin, valproic acid, oral anticoagulants such as warfarin, corticosteroids, chlorpheniramine,diphenhydramine, penicillin G, furosemideSalix, and
other NSAIDS such as aspirin and flunixin Banamine, since interactions may occur.
Phenylbutazone may affect laboratory test results for thyroid hormone.
Not for use in horses hypersensitive allergic to phenylbutazone.
Do not use in horses with stomach ulcers or a history of stomach ulcers, horses that are anemic, or have diseases of the bone marrow, kidney, liver, or heart.
Do not use in pregnant or lactating horses unless benefits outweigh the risks.
Avoid use in debilitated horses, foals, and ponies unless benefits outweigh the risks,since the possibility of toxic side effects is increased in these animals
Side Effects:
May see signs of oral or gastric ulcers. In adult horses these signs may include decreased appetite, weight loss, mild colic, poor performance, depression, lying down more than normal, diarrhea, accumulation
of fluid under the belly, and anemia withsigns of pale gums and weakness.
In foals may also see teeth grinding, drooling, weakness, and nursing for only shortperiods of time.
Effects related to the kidney may result in changes in drinking or urination habits.
Stop using phenylbutazone and consult your veterinarian if you notice any of the above side effects.
If your horse experiences an allergic reaction to the medication, signs may include facial swelling, hives, scratching, sudden onset of diarrhea, shock, seizures, pale gums, cold limbs, or coma.
If you observe any of these signs, contact your veterinarian immediately.
Instructions
ADMINISTRATION AND DOSAGE:
Orally - 1 to 2 g of phenylbutazone per 500 lb of body weight, but not to exceed 4 g daily. Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
Guidelines to Successful Therapy:
1. Use a relative high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
2. Response to BUTAPASTE therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.
3. When administering BUTAPASTE the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.
4. Many chronic conditions will respond to BUTAPASTE therapy but discontinuance of treatment may result in recurrence of symptoms.
STORAGE:
Store at 15°-30°C (59°-86°F).
